Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19 (PROTECT), a Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety Among Asymptomatic to Moderately-severe, Ambulatory Patients.

NCT05096052 is registered in ClinicalTrials.gov with Bioxytran Inc. as lead sponsor.

NCT NCT05096052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05096052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19 (PROTECT), a Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety Among Asymptomatic to Moderately-severe, Ambulatory Patients.
Lead sponsor
Bioxytran Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
April 1, 2022
Completion date
September 25, 2022
Enrollment
408 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, covid-19 pandemic, covid-19 respiratory infection, cytokine release syndrome, sars-cov2 infection